Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054218 · ClinicalTrials.gov registry record
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
A clinical trial, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- 336
- Enrollment target
NCT05054218 is a clinical trial that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 336 participants.
The verdict
NCT05054218 has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- 336 participants
- Enrollment target
Study Summary
Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose
Interventions
- BIOLOGICAL mRNA-1273
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2022-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05054218
The ClinicalTrials.gov registry entry for NCT05054218 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mRNA-1273 is the first listed.
NCT05054218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05054218 about?
NCT05054218 is a clinical study titled "COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients". Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose
What is the current status of trial NCT05054218?
This trial is currently completed. The enrollment target is 336 participants. The study started on 2021-09-10. Estimated completion is 2022-08-29.
What interventions are being tested in trial NCT05054218?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05054218?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.